Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Cahn

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
Diabetes, Obesity & Metabolism|April 28, 2026
Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver FibrosisJan Oscarsson, Monika Huhn, Yunyun Jiang, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Journal of Diabetes and Its Complications|November 29, 2025
Current primary care approaches to diabetic foot prevention and treatmentMahmoud Ibrahim, Ebtesam M Ba-Essa, Asma Ahmed, et al.
Diabetes/Metabolism Research and Reviews|May 15, 2018
Global status of diabetes prevention and prospects for action: A consensus statementMahmoud Ibrahim, Jaakko Tuomilehto, Pablo Aschner, et al.
The Journal of Infectious Diseases|April 1, 2024
Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome ParametersOmer Bar Ziv, Avivit Cahn, Tallulah Jansen, et al.
Diabetes, Obesity & Metabolism|February 25, 2020
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trialHarpreet S Bajaj, Itamar Raz, Ofri Mosenzon, et al.
Diabetes/Metabolism Research and Reviews|April 29, 2020
Hypoglycaemia and its management in primary care settingMahmoud Ibrahim, Jason Baker, Avivit Cahn, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
Diabetes, Obesity & Metabolism|April 28, 2026
Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver FibrosisJan Oscarsson, Monika Huhn, Yunyun Jiang, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Journal of Diabetes and Its Complications|November 29, 2025
Current primary care approaches to diabetic foot prevention and treatmentMahmoud Ibrahim, Ebtesam M Ba-Essa, Asma Ahmed, et al.
Diabetes/Metabolism Research and Reviews|May 15, 2018
Global status of diabetes prevention and prospects for action: A consensus statementMahmoud Ibrahim, Jaakko Tuomilehto, Pablo Aschner, et al.
The Journal of Infectious Diseases|April 1, 2024
Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome ParametersOmer Bar Ziv, Avivit Cahn, Tallulah Jansen, et al.
Diabetes, Obesity & Metabolism|February 25, 2020
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trialHarpreet S Bajaj, Itamar Raz, Ofri Mosenzon, et al.
Diabetes/Metabolism Research and Reviews|April 29, 2020
Hypoglycaemia and its management in primary care settingMahmoud Ibrahim, Jason Baker, Avivit Cahn, et al.
Pageof 10